1. Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor
- Author
-
Marcus Bantscheff, Daniel Poeckel, Ramanjulu Joshi M, Jessica Perrin, Christina Rau, Katrin Strohmer, Birgit Duempelfeld, Nico Zinn, G. Scott Pesiridis, Giovanna Bergamini, Marcel Muelbaier, Douglas W. Thomson, Anne J. Wagner, Viera Kasparcova, and Alan P. Graves
- Subjects
010405 organic chemistry ,Kinase ,Chemistry ,Organic Chemistry ,IκB kinase ,01 natural sciences ,Biochemistry ,0104 chemical sciences ,Cell biology ,010404 medicinal & biomolecular chemistry ,TANK-binding kinase 1 ,Interferon ,Drug Discovery ,medicine ,Phosphorylation ,Signal transduction ,Protein kinase A ,medicine.drug ,Interferon regulatory factors - Abstract
[Image: see text] The serine/threonine protein kinase TBK1 (Tank-binding Kinase-1) is a noncanonical member of the IkB kinase (IKK) family. This kinase regulates signaling pathways in innate immunity, oncogenesis, energy homeostasis, autophagy, and neuroinflammation. Herein, we report the discovery and characterization of a novel potent and highly selective TBK1 inhibitor, GSK8612. In cellular assays, this small molecule inhibited toll-like receptor (TLR)3-induced interferon regulatory factor (IRF)3 phosphorylation in Ramos cells and type I interferon (IFN) secretion in primary human mononuclear cells. In THP1 cells, GSK8612 was able to inhibit secretion of interferon beta (IFNβ) in response to dsDNA and cGAMP, the natural ligand for STING. GSK8612 is a TBK1 small molecule inhibitor displaying an excellent selectivity profile and therefore represents an ideal probe to further dissect the biology of TBK1 in models of immunity, neuroinflammation, obesity, or cancer.
- Published
- 2019
- Full Text
- View/download PDF